Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)

Primary Objective The primary objective of this phase I-II study is to evaluate: * Phase I: Assess the maximum tolerated dose (MTD) of bortezomib in a weekly schedule with bevacizumab given every 3 weeks. * Phase II: Using the MTD established in phase I, assess efficacy of the combination as indicated by progression-free survival. Secondary Objectives The secondary objectives of this study are to evaluate: * Response rates and duration of response * 1 year survival * Overall survival * Qualitative and quantitative toxicity * Circulating endothelial cells (CECs) prior to treatment, prior to cycle 2, and/or at the time of progression